diphenyl has been researched along with Diabetes Mellitus, Type 2 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adelusi, T; Chowdhry, A; Du, L; Gu, X; Hao, M; Li, X; Lu, Q; Sun, Y; Xu, L; Yin, X; Zhou, X | 1 |
| Abbas, AHS; Babkov, DA; Brigadirova, AA; Ghosh, K; Kolodina, AA; Morkovnik, AS; Prilepskaya, DR; Sobhia, ME; Spasov, AA; Zhukovskaya, ON | 1 |
| Al-Harrasi, A; El-Kott, AF; Halim, SA; Hussain, J; Khalid, M; Khan, A; Naseer, MM; Negm, S; Pasha, AR; Shafiq, Z; Ullah, S | 1 |
| Chen, Y; Jiang, H; Li, Z; Liu, Y; Qian, H; Zhang, L; Zhang, Y | 1 |
| Babkov, DA; Babkova, VA; Borisov, AV; Borodkin, GS; Brigadirova, AA; Kolodina, AA; Litvinov, RA; Morkovnik, AS; Sochnev, VS; Sokolova, EV; Spasov, AA; Zhukowskaya, ON | 1 |
5 other study(ies) available for diphenyl and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Novel Chalcone BDD-39 Mitigated Diabetic Nephropathy through the Activation of Nrf2/ARE Signaling.
Topics: Animals; Biphenyl Compounds; Chalcone; Chalcones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Mice; NF-E2-Related Factor 2; Oxidative Stress; RNA; Signal Transduction | 2022 |
Discovery and evaluation of biphenyl derivatives of 2-iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Hypoglycemic Agents; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats | 2023 |
Synthesis of new diphenyl urea-clubbed imine analogs and its Implications in diabetic management through in vitro and in silico approaches.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Imines; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2023 |
Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Topics: Animals; Binding Sites; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Design; Glucose Tolerance Test; Humans; Hydrogen Bonding; Hypoglycemic Agents; Male; Methylamines; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Propionates; Protein Structure, Tertiary; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2018 |
Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
Topics: AMP-Activated Protein Kinases; Animals; Benzimidazoles; Biphenyl Compounds; Cattle; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Enzyme Activators; Glycosylation; Hypoglycemic Agents; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide; Serum Albumin, Bovine; Solubility; Structure-Activity Relationship | 2019 |